{
  "trial_id": "NCT02365480",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, race, duration of ulcerative colitis, UCDAI score, maintenance therapy with mesalamine duration, ECOG performance status, leukocyte count, absolute neutrophil count, platelet count, total bilirubin level, AST level, ALT level, creatinine level, use of contraception, history of immunomodulatory treatment, use of CYP isozymes affecting medicines, history of allergic reactions to similar compounds, presence of dysplasia-associated mass or lesion, history of investigational agent use, presence of uncontrolled intercurrent illness, HIV status, pregnancy status, breastfeeding status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Region of Enrollment",
        "BMI"
      ],
      "remaining_candidate_features": [
        "duration of ulcerative colitis",
        "UCDAI score",
        "maintenance therapy with mesalamine duration",
        "ECOG performance status",
        "leukocyte count",
        "absolute neutrophil count",
        "platelet count",
        "total bilirubin level",
        "AST level",
        "ALT level",
        "creatinine level",
        "use of contraception",
        "history of immunomodulatory treatment",
        "use of CYP isozymes affecting medicines",
        "history of allergic reactions to similar compounds",
        "presence of dysplasia-associated mass or lesion",
        "history of investigational agent use",
        "presence of uncontrolled intercurrent illness",
        "HIV status",
        "pregnancy status",
        "breastfeeding status"
      ]
    },
    "processed-gen-response": "Age, gender, race, duration of ulcerative colitis, UCDAI score, maintenance therapy with mesalamine duration, ECOG performance status, leukocyte count, absolute neutrophil count, platelet count, total bilirubin level, AST level, ALT level, creatinine level, use of contraception, history of immunomodulatory treatment, use of CYP isozymes affecting medicines, history of allergic reactions to similar compounds, presence of dysplasia-associated mass or lesion, history of investigational agent use, presence of uncontrolled intercurrent illness, HIV status, pregnancy status, breastfeeding status."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Duration of Ulcerative Colitis, ECOG Performance Status, Leukocyte Count, Absolute Neutrophil Count, Platelet Count, Total Bilirubin, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Creatinine, Use of Maintenance Therapy with Mesalamine,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "BMI"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Duration of Ulcerative Colitis",
        "ECOG Performance Status",
        "Leukocyte Count",
        "Absolute Neutrophil Count",
        "Platelet Count",
        "Total Bilirubin",
        "Aspartate Aminotransferase (AST)",
        "Alanine Aminotransferase (ALT)",
        "Creatinine",
        "Use of Maintenance Therapy with Mesalamine"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Duration of Ulcerative Colitis, ECOG Performance Status, Leukocyte Count, Absolute Neutrophil Count, Platelet Count, Total Bilirubin, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Creatinine, Use of Maintenance Therapy with Mesalamine"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Ulcerative Colitis Duration, Ulcerative Colitis Disease Activity Index (UCDAI), Mesalamine Dose, ECOG Performance Status, Leukocytes, Absolute Neutrophil Count, Platelets, Total Bilirubin, AST, ALT, Creatinine.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "BMI"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Ulcerative Colitis Duration",
        "Ulcerative Colitis Disease Activity Index (UCDAI)",
        "Mesalamine Dose",
        "ECOG Performance Status",
        "Leukocytes",
        "Absolute Neutrophil Count",
        "Platelets",
        "Total Bilirubin",
        "AST",
        "ALT",
        "Creatinine"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Ulcerative Colitis Duration, Ulcerative Colitis Disease Activity Index (UCDAI), Mesalamine Dose, ECOG Performance Status, Leukocytes, Absolute Neutrophil Count, Platelets, Total Bilirubin, AST, ALT, Creatinine."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, duration of ulcerative colitis, UCDAI score, ECOG performance status, Karnofsky performance score, leukocyte count, absolute neutrophil count, platelet count, total bilirubin, AST, ALT, creatinine, history of dysplasia, history of colorectal cancer, maintenance therapy with mesalamine, concomitant medications.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment",
        "BMI"
      ],
      "remaining_candidate_features": [
        "duration of ulcerative colitis",
        "UCDAI score",
        "ECOG performance status",
        "Karnofsky performance score",
        "leukocyte count",
        "absolute neutrophil count",
        "platelet count",
        "total bilirubin",
        "AST",
        "ALT",
        "creatinine",
        "history of dysplasia",
        "history of colorectal cancer",
        "maintenance therapy with mesalamine",
        "concomitant medications"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, duration of ulcerative colitis, UCDAI score, ECOG performance status, Karnofsky performance score, leukocyte count, absolute neutrophil count, platelet count, total bilirubin, AST, ALT, creatinine, history of dysplasia, history of colorectal cancer, maintenance therapy with mesalamine, concomitant medications."
  }
}